iScience Interventional, Inc Enters into a Collaborative Supply Agreement with Centocor Research and Development, Inc on a Minimally-Invasive Approach to Deliver Cell Therapies

MENLO PARK, Calif.--(BUSINESS WIRE)--iScience Interventional, pioneers of site-specific therapies for anterior and posterior ocular diseases, announced it has signed a collaborative agreement with Centocor R&D, Inc. iScience will supply micro-catheter delivery systems for use in the clinical evaluation of cell therapies used in the treatment of retinal degeneration.

“We are pleased to work with Centocor in exploring the new site-specific therapeutic opportunities enabled by this access device”

“We are pleased to work with Centocor in exploring the new site-specific therapeutic opportunities enabled by this access device,” commented Michael F. Nash, President & CEO of iScience Interventional. “We believe that the iTrack™ family of micro-catheters will have a significant role in the creation of numerous treatments for unmet clinical needs that dramatically impact patients vision. The advent of micro-catheter technology provides unprecedented access to anatomical structures in both the anterior and posterior segments of the eye.”

About iScience Interventional

The iTrack™ 275 is one of a platform of novel devices dedicated to the pursuit and growth of minimally invasive ophthalmic procedures. Interventional ophthalmology has changed the way patients around the world are receiving care through the utilization of iScience Interventional’s microsurgical instruments and imaging equipment. In addition to giving glaucoma patients an advanced minimally-invasive surgical option, the Company has also launched several new products for retina surgery within the past year.